Profile data is unavailable for this security.
About the company
Anika Therapeutics, Inc. is a global joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care, including in the areas of osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. It is focused on developing, manufacturing and commercializing products on its hyaluronic acid (HA), technology platform. Its OA Pain Management product family consists of Monovisc and Orthovisc, its injectable, HA, OA Pain Management offerings are indicated to provide pain relief from osteoarthritis conditions; and Cingal, its novel, next generation, single-injection OA Pain Management product consisting of its proprietary cross-linked HA material combined with a steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products utilizing HA, including Integrity, its new hyaluronic acid-based scaffold for rotator cuff and other tendon repairs.
- Revenue in USD (TTM)164.17m
- Net income in USD-97.52m
- Incorporated2018
- Employees357.00
- LocationAnika Therapeutics Inc32 Wiggins AveBEDFORD 01730-2315United StatesUSA
- Phone+1 (781) 457-9000
- Fax+1 (781) 305-9720
- Websitehttps://anika.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accuray Inc | 444.20m | -20.08m | 194.09m | 987.00 | -- | 4.29 | -- | 0.4369 | -0.2032 | -0.2032 | 4.48 | 0.4503 | 0.9353 | 2.01 | 5.25 | 450,054.70 | -4.23 | -1.37 | -7.35 | -2.33 | 31.09 | 36.43 | -4.52 | -1.55 | 0.8655 | -0.0936 | 0.7901 | -- | -0.2355 | 1.29 | -67.51 | -- | -3.54 | -- |
| InfuSystem Holdings Inc | 132.78m | 1.48m | 198.39m | 499.00 | 138.45 | 3.57 | 14.45 | 1.49 | 0.0674 | 0.0674 | 6.15 | 2.61 | 1.28 | 10.28 | 6.29 | 266,100.20 | 1.43 | 4.60 | 1.68 | 5.69 | 50.51 | 56.43 | 1.12 | 4.07 | 1.59 | 2.88 | 0.3351 | 0.00 | 14.44 | 13.38 | 4,744.44 | -- | 6.01 | -- |
| Sight Sciences Inc | 79.54m | -50.35m | 203.53m | 214.00 | -- | 2.13 | -- | 2.56 | -1.01 | -1.01 | 1.60 | 1.88 | 0.4968 | 1.55 | 5.33 | 371,696.30 | -31.45 | -38.78 | -34.47 | -42.20 | 85.11 | 80.74 | -63.30 | -105.14 | 9.74 | -222.93 | 0.2645 | -- | 13.63 | 60.84 | 35.59 | -- | 6.77 | -- |
| Orchestra Biomed Holdings Inc | 2.65m | -57.69m | 218.25m | 56.00 | -- | 4.74 | -- | 82.45 | -1.60 | -1.60 | 0.0734 | 1.22 | 0.0276 | 1.04 | 26.34 | 47,267.86 | -60.19 | -- | -74.93 | -- | 92.71 | -- | -2,179.34 | -- | 4.21 | -- | 0.00 | -- | -21.88 | -- | -37.91 | -- | -- | -- |
| Inogen Inc | 331.52m | -52.69m | 223.42m | 834.00 | -- | 1.20 | -- | 0.6739 | -2.25 | -2.25 | 14.09 | 7.78 | 1.02 | 7.81 | 8.03 | 397,506.00 | -16.21 | -8.23 | -20.38 | -9.53 | 44.22 | 44.54 | -15.89 | -10.31 | 2.34 | -- | 0.00 | -- | -16.32 | -2.49 | -22.30 | -- | 26.34 | -- |
| Utah Medical Products, Inc. | 44.08m | 15.26m | 227.02m | 169.00 | 15.27 | 1.81 | 12.36 | 5.15 | 4.27 | 4.27 | 12.36 | 36.09 | 0.3378 | 1.93 | 12.23 | 260,816.60 | 11.69 | 12.69 | 12.05 | 13.19 | 58.80 | 61.57 | 34.62 | 30.51 | 26.94 | -- | 0.00 | 37.05 | -3.93 | 3.64 | 0.9834 | 1.65 | 9.71 | 1.86 |
| Trubridge Inc | 337.67m | -58.25m | 246.86m | 3.22k | -- | 1.43 | -- | 0.7311 | -4.09 | -4.09 | 23.67 | 11.57 | 0.8126 | 183.56 | 5.84 | 104,900.30 | -14.40 | 1.25 | -16.50 | 1.41 | 49.31 | 50.40 | -17.72 | 1.56 | 1.78 | 0.8055 | 0.5052 | 45.06 | 3.91 | 3.89 | -387.73 | -- | 88.71 | -- |
| Anika Therapeutics Inc | 164.17m | -97.52m | 248.54m | 357.00 | -- | 1.39 | -- | 1.51 | -6.64 | -6.64 | 11.14 | 12.24 | 0.5868 | 1.47 | 5.21 | 459,854.30 | -34.86 | -5.41 | -38.55 | -5.87 | 62.70 | 60.70 | -59.40 | -12.60 | 3.78 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
| LifeMD Inc | 193.06m | -25.61m | 249.80m | 207.00 | -- | -- | -- | 1.29 | -0.6409 | -0.6409 | 4.85 | -0.1847 | 3.41 | 6.21 | 36.89 | 932,652.80 | -39.18 | -153.05 | -240.82 | -526.91 | 89.64 | 83.66 | -11.49 | -45.44 | 0.7805 | -8.83 | 1.49 | -- | 28.15 | 78.90 | 51.27 | -- | 143.64 | -- |
| Electromed Inc | 57.06m | 6.47m | 250.38m | 174.00 | 41.06 | 6.07 | 34.22 | 4.39 | 0.7256 | 0.7256 | 6.40 | 4.91 | 1.23 | 3.37 | 2.42 | 327,931.00 | 13.91 | 8.64 | 16.22 | 10.09 | 76.62 | 76.26 | 11.34 | 8.06 | 5.06 | -- | 0.00 | 0.00 | 13.83 | 11.82 | 62.67 | 21.06 | -22.23 | -- |
| Atlantic International Corp | 313.06m | -68.07m | 259.76m | 7.00 | -- | 14.47 | -- | 0.8297 | -5.55 | -5.55 | 12.45 | 0.358 | 4.44 | -- | 10.48 | 44,723,330.00 | -96.45 | -71.97 | -233.48 | -106.09 | 10.81 | 61.01 | -21.74 | -1,471.82 | -- | -1.64 | 0.8328 | -- | -100.00 | -- | -37.43 | -- | -- | -- |
| Zynex Inc | 193.67m | 4.82m | 263.04m | 1.10k | 55.78 | 7.47 | 28.13 | 1.36 | 0.1481 | 0.1481 | 5.91 | 1.11 | 1.40 | 2.57 | 7.05 | 176,059.10 | 3.48 | 14.58 | 4.06 | 17.52 | 80.20 | 79.62 | 2.49 | 10.44 | 3.15 | 4.15 | 0.6246 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Pulmonx Corp | 79.30m | -57.11m | 268.12m | 279.00 | -- | 2.85 | -- | 3.38 | -1.47 | -1.47 | 2.04 | 2.38 | 0.45 | 1.24 | 7.29 | 284,236.60 | -32.41 | -26.27 | -36.42 | -28.97 | 74.16 | 71.95 | -72.01 | -93.76 | 6.77 | -- | 0.2839 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| AngioDynamics, Inc. | 292.73m | -243.03m | 277.53m | 748.00 | -- | 1.42 | -- | 0.9481 | -6.04 | -6.04 | 7.25 | 4.79 | 0.7434 | 2.27 | 6.55 | 391,344.90 | -61.72 | -16.38 | -74.39 | -18.70 | 51.71 | 52.95 | -83.02 | -30.49 | 1.41 | -- | 0.00 | -- | -10.28 | 2.35 | -251.53 | -- | 13.09 | -- |
| OraSure Technologies, Inc. | 224.26m | 11.37m | 289.43m | 638.00 | 25.77 | 0.6801 | 11.82 | 1.29 | 0.1506 | 0.1506 | 3.01 | 5.71 | 0.4862 | 2.64 | 5.58 | 351,509.40 | 2.72 | 0.7238 | 2.94 | 0.8212 | 42.26 | 46.94 | 5.59 | 1.13 | 11.20 | -- | 0.0004 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Neuropace Inc | 76.45m | -28.09m | 289.53m | 171.00 | -- | 29.41 | -- | 3.79 | -0.9924 | -0.9924 | 2.70 | 0.3299 | 0.7817 | 1.83 | 6.69 | 447,087.70 | -28.72 | -- | -33.44 | -- | 73.83 | -- | -36.74 | -- | 4.77 | -4.06 | 0.8578 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Anika Therapeutics Inc's reporting currency: US Dollar USD
57.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Trigran Investments, Inc.as of 30 Sep 2024 | 2.12m | 14.36% |
| Caligan Partners LPas of 30 Sep 2024 | 1.44m | 9.70% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 1.05m | 7.08% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 783.87k | 5.30% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 668.59k | 4.52% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 574.23k | 3.88% |
| BlackRock Financial Management, Inc.as of 30 Sep 2024 | 526.33k | 3.56% |
| Boothbay Fund Management LLCas of 30 Sep 2024 | 503.84k | 3.41% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 448.78k | 3.03% |
| Geode Capital Management LLCas of 30 Sep 2024 | 324.96k | 2.20% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
